Minodronic acid
- Generic Name
- Minodronic acid
- Drug Type
- Small Molecule
- Chemical Formula
- C9H12N2O7P2
- CAS Number
- 180064-38-4
- Unique Ingredient Identifier
- 40SGR63TGL
- Indication
Investigated for use/treatment in multiple myeloma, breast cancer, osteoporosis, and lung cancer.
Denosumab Shows Superior Fracture Prevention in Dialysis Patients Despite Cardiovascular Risks
• Japanese study reveals denosumab reduces fracture risk by 45% compared to oral bisphosphonates in dialysis patients over three years, particularly effective for nonvertebral fractures.
• Research identifies potential cardiovascular concerns, with denosumab users showing 3.5 times higher risk of acute myocardial infarction compared to bisphosphonate users.
• Findings highlight important clinical trade-offs, as denosumab's independence from kidney clearance makes it valuable for dialysis patients, despite FDA's recent boxed warning for severe hypocalcemia risk.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath